Histology services provider and specialist in tissue analysis, Immunohistochemistry and In Situ Hybridization since 2005.
Slide of the month
First multiplex IHC protocol on bone marrow decalcified by HISTALIM.
Make your quote online
Histalim is a service provider company in histology, immunohistochemistry (IHC), in situ hybridization (ISH), and image analysis. Our laboratory located in Montpellier was founded in 2005. This positioning shows our willingness to meet the increasing demand to design, develop, and validate protocols based on standard and/or innovative techniques.
Our specialized services take part in research and development projects for pharmaceutic products, medical devices, and diagnostic tools… and in other domains like dermo-cosmetic, ecotoxicity, food industry… We are particularly engaged in the development of new therapies in the domains of oncology and chronic diseases i.e. therapeutic antibody, and new generation diagnostic tools i.e. circulating biomarkers. Histalim positions its strategic growth specifically in the development of therapeutic antibodies issues.
Our activities are conformed to Good Laboratory Practices (GLP) and our laboratory is authorized to perform studies with human tissue samples. Histalim can also offer to perform in-house research and development projects. This particularity allows us to provide some customized services to our customers, with innovative technologies. Therefore we can provide a large range of expert services like Tissue Cross Reactivity (TCR) studies, Tissue MicroArray (TMA), and Fluorescent ISH (FISH)…
- 19 January 2018Read more
Injectable medical devices respond to the definition of a long-term, invasive, surgical device since they are introduced invasively into...
- 1 September 2017Read more
Domenico LAZZARO, M.D pathologist, joins HISTALIM which enforces thanks to his expertise its positioning on the tumor immuno-profiling. HISTALIM...
- 24 July 2017Read more
…through a collaborative R&D program of 29 million euros, endorsed by BPIfrance. Describe with high fidelity the tumor immune...